AbbVie · Immunology Discovery Pathology, Bioresearch Center
AbbVie’s Immunology Discovery Pathology group at the Worcester, MA Bioresearch Center reads inflamed human tissue with both protein and RNA spatial methods. Its October 2026 rheumatoid arthritis study pairs a multiplex immunofluorescence protein panel with CosMx, Xenium, Visium and laser capture proteomics on the same synovial blocks.
Why Now
The group is hiring for multiplexed image analysis in the same month it published its rheumatoid arthritis (RA) spatial work. A Senior Scientist, Informatics II role in Immunology Discovery Pathology was posted October 12, 2026; it names multiplex immunofluorescence (mIF), imaging mass cytometry, high-plex spatial proteomics, and RA or inflammatory bowel disease experience. On October 16, 2026 Frontiers in Immunology published a multiomic map of 12 synovial FFPE blocks: 6 RA, 3 osteoarthritis, 3 healthy, run across CosMx 1K, Xenium (377 genes plus 40 custom, and Prime 5K), Visium, laser capture LC/MS proteomics and mIF. The protein read was the PhenoCode Signature Immune Profile Human panel with a conjugated CD248 antibody, on slides already imaged with Xenium. The paper points ahead to treatment-naive, responsive and refractory RA cohorts.
Sources: Xtalks listing, AbbVie Senior Scientist, Informatics II, Worcester, posted Oct 12, 2026 · Front Immunol, Oct 16, 2026 (PMC13719634), spatial multiomics of RA synovial niches · Front Toxicol, Jun 2026 (PMC13357943), spatial transcriptomics in safe drug development, AbbVie Investigative Toxicology and Pathology co-author
Opportunity Size
One discovery pathology group with a 12-block synovial reference set, co-authors at 3 AbbVie sites (Worcester, Cambridge, North Chicago), and a newly posted computational role. Sized for one RA panel comparison first; the posting’s inflammatory bowel disease line is the second tissue to ask about.
ICP Fit
The group’s October 2026 Methods name the PhenoCode Signature Immune Profile Human Protein Panel on slides also run on Xenium, and its October 2026 posting names mIF and imaging mass cytometry by name.
Your Play
Ask a pathology author on the Frontiers paper for one panel comparison on serial sections from the 4 RA and 1 healthy blocks already run on Xenium.
Reach a pathology author on the Frontiers paper, since tissue selection sits with pathology, and bring the informatics lead who will own the new role’s pipelines. Propose one run on serial sections from the 4 RA and 1 healthy blocks already profiled with Xenium and the PhenoCode panel, scored against the paper’s own niches: lymphoid (CD74+, CXCL12+), vascular (NOTCH3+, mural) and stromal (POSTN+, DKK3+, CD34+). The question to settle is whether deeper protein plex separates those fibroblast subtypes further on the same tissue.
Sources: Front Immunol, Oct 2026, Methods and Discussion
Your October Frontiers in Immunology paper mapped up to 9 fibroblast subtypes across the lining and sublining of RA synovium in 12 blocks, and the group posted a multiplexed imaging informatics role on October 12. My read is that the treatment-refractory cohorts you describe next will arrive as needle biopsies, where each section has to answer more protein questions than a large block does.
Where we may be able to help is reading more protein targets per section, checked against your own CD74+, NOTCH3+ and POSTN+ niches.
Would you scope one run on serial sections from the 4 RA and 1 healthy blocks already imaged with Xenium?”
Positioning & Caveats
Open on the paper’s stated limits: low sample number, limited clinical information, and blocks bought from commercial vendors, so the authors treat these as a histomolecular reference rather than a clinical cohort. Position as added protein depth beside CosMx, Xenium and the PhenoCode panel, not as a swap; this group benchmarks platforms against each other and will expect a side-by-side on its own tissue. Confirm antibody coverage for CD248 and the fibroblast markers early, since the acknowledgments thank a colleague for conjugating CD248 in-house. The open role is computational, so read it as evidence of imaging data volume, not of a pending instrument purchase.
Key Personas – Buying Committee
- POWER USERScientist, Immunology Discovery PathologyEmail✓LinkedIn✓
- POWER USERSenior Scientist, Informatics IIEmail✓LinkedIn✓
- CHAMPION BUYERPathologist, Pathology Department, Immunology Discovery ResearchEmail✓LinkedIn✓
- BUDGET HOLDERHead, Immunology Discovery PathologyEmail✓LinkedIn✓
- STRATEGIC BUYLeadership, Immunology Discovery ResearchEmail✓LinkedIn✓
Delivered reports name each person, with email, LinkedIn, and a first message. A check means verified.



